Member Info for beinthelead

Good honest post, blackcat. There’s too many that boast about buying low, selling high. Your story (albeit slightly more extreme) will mirror more people than you think.

If AVA data is good, I’m not sure Avacta will exist in 2026. As you say, it’s not going from 0-100 overnight. There’ll be derisking inflection points along the way.

Here’s to hoping and waiting. Take it easy.

Seems very confident and specific at the same time.

https://twitter.com/Abingdon_Health/status/1486741536675143684?s=20&t=ZORvF_7S-py-Uz_IRZvE0g

Rxdav - agreed.

The broker did not attribute huge value to the LFT.

Not too dissimilar?? Surely you can believe what you’ve just written? Give it up Wyn. You are trolling the board incessantly. Why are you still here at this low SP?

I said it the other day; the trolling is now very desperate. The last line of defence is the P3 trial question. Trolling is now an outgoing concern.

“ Fundamentals crush any hocus pocus every time” would suggest this on a T-shirt, or pen. Perfect.

Agreed. When all’s said and done, people will be more in tune with passing on nasties. In terms of testing, I now naturally test before going to see and ill relative. That layer of protection wasn’t there before. It is now, so I use it.

Is it a billion dollar overnight opp, ala 2020; I don’t think so. Interesting to see it play out. Positively, we’re ahead of the curve with Self use CE.

Wyn - what’s your point? That’s lots of words to imply testing is no longer required.

This board is finally done with the negativity. Contrary view? It’s not. It’s a fishing trip.

Reflection is powerful. The LFT disaster from a few weeks ago has shaken off most of the Covid value in the SP. Like it or not. But the benefit; this trolling angle is no longer valid here. Kinda why the bishop is repeating themselves over and over, running out of material.

Get the message. We’re done with LFT trolling. Is AVA P3 required?? Who cares!!! If P1 proves successful, we’ll have bigger things to worry about.

SureScreen.

Courtesy of Tom_the_bomb

https://twitter.com/tom_the_bomb__/status/1485719015377059851?s=20

Neil Bell literally says that AVA3996’s clinical selection was constrained by successful AVA6000 data.

Don’t think it was my confirmation bias…

Agreed. I just hope for less ambiguous waffle, and more of a confident presentation of data to date. They have the power and control to censor the data as they wish, provided they inform the market of its strength in terms of price sensitivity.

Be nice to shake off the short interest. That has been/is far more damaging than the latest LFT fiasco.

Hi Gmcc - why do you expect it to be more than a few months if AVA data is good? Would you not expect us to be half our ATH based on this alone?? No sarcasm.

Is it a new one??

Certainly looking like somebody buying a bit today. Could be correct, Codejunkie.

He did, and he should share it as he planned.

The, ‘not available until post P1a’ and ‘6 weeks Covid delay’ is guess work.

I think it was Sparticus that supported NDN’s ‘balanced’ views the other night. What a joke that was. His previous two posts are clear as day - he hates Avacta and hates anyone who is likely to benefit. Chiefly, Myles.

“… we [POINT] became a sublicensee of AVACTA’s license for using the intellectual property of developing and marketing radiopharmaceutical agents.”

What a plague.

It must be hard work finding the thing to troll. We all know the tech is licensed from Bach. No news. However, this new NDN angle is rhubarb.

From POINT’s IPO:

“In December 2020, we entered into an agreement with AVACTA (“AVACTA Agreement”). Under the AVACTA Agreement, we became a sublicensee of AVACTA’s license for using the intellectual property of developing and marketing radiopharmaceutical agents. Under this agreement, we obtained an exclusive license of AVACTA’s patent rights to use, develop, manufacture and commercialize any FAP-activated PSMA targeted radiopharmaceutical and a non-exclusive license of AVACTA’s patent rights for other FAP-activated radiopharmaceuticals arising from the licensed technology.”

Exactly.

My optimistic Sunday feeling is hoping for a bullish outlook on the LFT. I.e. more detail/progress on the ABDX partnership. It would be a crying shame if zero revenue is attributed from it. Even a working platform, with the threat of sales will swing the bargaining power closer to Avacta. Without it, licensing premium could be reduced.

Hugely excited for data.

Cellar Boy & Poirot need their own board.

https://twitter.com/boy_cellar/status/1484886539721375744?s=20

G-Man. Agree the BB would be nice without the abuse.

But checkout this thread https://twitter.com/BRINGIT46172402/status/1484252570554335232?s=20. Now suggesting Myles is used for cancer drug experimentation?

We hear a lot about Twitter trolls being cancelled or punished by the authorities for far less. LSE will not ban these people. It’s allowed to breed - look how many have joined in? Bullying.

The shorter is back. Reading that was painful.

Is the share delivering on your short?